Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases

Journal of Autoimmunity

Volumn 37, Issue 4, 2011, Pages 273-288

  Borchers, Andrea T ^a   Leibushor, Naama ^a   Cheema, Gurtej S ^a   Naguwa, Stanley M ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Biologic agents; Immunosuppression; Infection and immunity

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL FACTOR; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URSODEOXYCHOLIC ACID;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; DRUG TOLERABILITY; HUMAN; IMMUNOBIOLOGY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATIC DISEASE; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; GRANULOMA; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERFERON-ALPHA; MYCOBACTERIUM TUBERCULOSIS; RHEUMATIC DISEASES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82955217794     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.08.002     Document Type: Review

References (228)

1. Pichler W.J. Adverse side-effects to biological agents. Allergy 2006, 61:912-920.
2. Hausmann O.V., Seitz M., Villiger P.M., Pichler W.J. The complex clinical picture of side effects to biologicals. Med Clin North Am 2010, 94:791-804. xi-ii.
3. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.-Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
4. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
5. Shealy D., Cai A., Staquet K., Baker A., Lacy E.R., Johns L., et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010, 2.
6. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
7. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
8. Mitoma H., Horiuchi T., Tsukamoto H., Tamimoto Y., Kimoto Y., Uchino A., et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008, 58:1248-1257.
9. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S., Kikuchi Y., et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005, 128:376-392.
10. Shen C., Assche G.V., Colpaert S., Maerten P., Geboes K., Rutgeerts P., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21:251-258.
11. Lügering A., Schmidt M., Lügering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
12. Emi Aikawa N., de Carvalho J.F., Artur Almeida Silva C., Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010, 38:82-89.
13. Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005, 34:19-22.
14. Arends S., Lebbink H.R., Spoorenberg A., Bungener L.B., Roozendaal C., van der Veer E., et al. The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010, 28:661-668.
15. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
16. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G.R., Bennett R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012.
17. van der Bijl A.E., Breedveld F.C., Antoni C.E., Kalden J.R., Kary S., Burmester G.R., et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-1028.
18. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
19. Jones G., Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:81-89.
20. Haggerty H.G., Abbott M.A., Reilly T.P., DeVona D.A., Gleason C.R., Tay L., et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 2007, 34:2365-2373.
21. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
22. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657-661.
23. Paltiel M., Gober L.M., Deng A., Mikdashi J., Alexeeva I., Saini S.S., et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol 2008, 144:1190-1194.
24. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:189-194.
25. Khraishi M., Russell A., Olszynski W.P. Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther 2010, 32:1855-1870.
26. Campi P., Benucci M., Manfredi M., Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007, 7:393-403.
27. Bavbek S., Aydin O., Ataman S., Cahill K., Castells M. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011.
28. Eriksson C., Engstrand S., Sundqvist K.G., Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 2005, 64:403-407.
29. Desai D., Goldbach-Mansky R., Milner J.D., Rabin R.L., Hull K., Pucino F., et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother 2009, 43:967-972.
30. Zeltser R., Valle L., Tanck C., Holyst M.M., Ritchlin C., Gaspari A.A. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001, 137:893-899.
31. Rajakulendran S., Deighton C. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. Rheumatology (Oxford) 2004, 43:1588-1589.
32. Winfield H., Lain E., Horn T., Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol 2006, 142:218-220.
33. González-López M.A., Martinez-Taboada V.M., González-Vela M.C., Blanco R., Fernández-Llaca H., Rodríguez-Valverde V., et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007, 32:672-674.
34. Werth V.P., Levinson A.I. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol 2001, 137:953-955.
35. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
36. Wallis R.S., Broder M., Wong J., Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39:1254-1255.
37. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Cöster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986-1992.
38. Gómez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
39. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
40. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
41. Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Breban M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
42. Wallis R.S. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007, 12:16-21.
43. Furst D.E., Wallis R., Broder M., Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006, 36:159-167.
44. Harris J., Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010, 161:1-9.
45. Netea M.G., Radstake T., Joosten L.A., van der Meer J.W., Barrera P., Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003, 48:1853-1857.
46. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194:486-492.
47. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A.M., Prejean M.V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006, 8:R114.
48. Ogata A., Mori M., Hashimoto S., Yano Y., Fujikawa T., Kawai M., et al. Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol 2010, 20:130-133.
49. Cope A.P., Londei M., Chu N.R., Cohen S.B., Elliott M.J., Brennan F.M., et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994, 94:749-760.
50. Zou J., Rudwaleit M., Brandt J., Thiel A., Braun J., Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003, 48:780-790.
51. Zou J., Rudwaleit M., Brandt J., Thiel A., Braun J., Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003, 62:561-564.
52. Berg L., Lampa J., Rogberg S., van Vollenhoven R., Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001, 60:133-139.
53. Baeten D., Van Damme N., Van den Bosch F., Kruithof E., De Vos M., Mielants H., et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001, 60:750-755.
54. Zou J.X., Braun J., Sieper J. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002, 20:S34-S37.
55. Schuerwegh A.J., Van Offel J.F., Stevens W.J., Bridts C.H., De Clerck L.S. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003, 42:541-548.
56. + T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999, 42:2166-2173.
57. Bobbio-Pallavicini F., Alpini C., Caporali R., Avalle S., Bugatti S., Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004, 6:R264-R272.
58. Cantaert T., van Baarsen L.G., Wijbrandts C.A., Thurlings R.M., van de Sande M.G., Bos C., et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:156-166.
59. Caramaschi P., Biasi D., Tonolli E., Pieropan S., Martinelli N., Carletto A., et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005, 26:58-62.
60. De Rycke L., Verhelst X., Kruithof E., Van den Bosch F., Hoffman I.E., Veys E.M., et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005, 64:299-302.
61. Bos W.H., Bartelds G.M., Wolbink G.J., de Koning M.H., van de Stadt R.J., van Schaardenburg D., et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008, 35:1972-1977.
62. Chen H.A., Lin K.C., Chen C.H., Liao H.T., Wang H.P., Chang H.N., et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:35-39.
63. Cuchacovich M., Catalan D., Wainstein E., Gatica H., Soto L., Aravena O., et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 2008, 26:1067-1073.
64. Bruns A., Nicaise-Roland P., Hayem G., Palazzo E., Dieude P., Grootenboer-Mignot S., et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009, 76:248-253.
65. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., de Portu S., Cecchini G., Cruini C., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006, 8:R3.
66. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8:515-519.
67. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005, 52:2192-2201.
68. Bacquet-Deschryver H., Jouen F., Quillard M., Ménard J.F., Goëb V., Lequerré T., et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008, 28:445-455.
69. Ferraro-Peyret C., Coury F., Tebib J.G., Bienvenu J., Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004, 6:R535-R543.
70. Cantaert T., De Rycke L., Mavragani C.P., Wijbrandts C.A., Niewold T.B., Niers T., et al. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis 2009, 68:1022-1029.
71. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den Bossche N., Van den Bosch F., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
72. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:437-449.
73. Jonsdottir T., Forslid J., van Vollenhoven A., Harju A., Brannemark S., Klareskog L., et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004, 63:1075-1078.
74. Ramos-Casals M., Roberto Perez A., Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
75. Petitpain N., Gambier N., Wahl D., Chary-Valckenaere I., Loeuille D., Gillet P. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009, 19:355-364.
76. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
77. Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011.
78. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
79. Ruiz Garcia V., Jobanputra P., Burls A., Cabello J.B., Galvez Munoz J.G., Saiz Cuenca E.S., et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2011, 2. CD007649.
80. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009, 84:979-984.
81. Williams V.L., Cohen P.R. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011, 50:619-625.
82. Debandt M., Vittecoq O., Descamps V., Le Loet X., Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003, 22:56-61.
83. Ramos-Casals M., Brito-Zeron P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
84. Icen M., Nicola P.J., Maradit-Kremers H., Crowson C.S., Therneau T.M., Matteson E.L., et al. Systemic lupus erythematosus features in rheumatoid arthritis and their effect on overall mortality. J Rheumatol 2009, 36:50-57.
85. Catrina A.I., Trollmo C., af Klint E., Engstrom M., Lampa J., Hermansson Y., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72.
86. Vigna-Pérez M., Abud-Mendoza C., Portillo-Salazar H., Alvarado-Sánchez B., Cuevas-Orta E., Moreno-Valdés R., et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005, 141:372-380.
87. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
88. Salmon-Ceron D., Tubach F., Lortholary O., Chosidow O., Bretagne S., Nicolas N., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70:616-623.
89. Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004, 63:681-687.
90. Kawashima M., Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis 2005, 64:415-418.
91. Pascual V., Banchereau J., Palucka A.K. The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 2003, 15:548-556.
92. Niewold T.B., Clark D.N., Salloum R., Poole B.D. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010. 948364.
93. Palucka A.K., Blanck J.P., Bennett L., Pascual V., Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005, 102:3372-3377.
94. Richez C., Schaeverbeke T., Dumoulin C., Dehais J., Moreau J.F., Blanco P. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther 2009, 11:R100.
95. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004.
96. van Baarsen L.G., Wijbrandts C.A., Rustenburg F., Cantaert T., van der Pouw Kraan T.C., Baeten D.L., et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010, 12:R11.
97. Crow M.K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010, 12(Suppl. 1):S5.
98. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40:233-240.
99. Mocciaro F., Renna S., Orlando A., Cottone M. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol 2009, 104:2867-2868.
100. Zidi I., Bouaziz A., Mnif W., Bartegi A., Al-Hizab F.A., Amor N.B. Golimumab therapy of rheumatoid arthritis: an overview. Scand J Immunol 2010, 72:75-85.
101. Florent A., Albert C., Giacchero D., Roux C., Euller-Ziegler L. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine 2010, 77:626-627.
102. Laurent S., Le Parc J.M., Clerici T., Breban M., Mahe E. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010, 163:1364-1365.
103. Dass S., Vital E.M., Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007, 56:2715-2718.
104. González-López M.A., Martínez-Taboada V.M., González-Vela M.C., Fernández-Llaca H., Val-Bernal J.F. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 2008, 158:1146-1148.
105. Peek R., Scott-Jupp R., Strike H., Clinch J., Ramanan A.V. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis 2006, 65:1259.
106. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215.
107. de Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
108. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005, 52:2513-2518.
109. Seneschal J., Milpied B., Vergier B., Lepreux S., Schaeverbeke T., Taieb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009, 161:1081-1088.
110. Richette P., Viguier M., Bachelez H., Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?. J Rheumatol 2007, 34:438-439.
111. Mease P., Genovese M.C., Gladstein G., Kivitz A.J., Ritchlin C., Tak P.P., et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011, 63:939-948.
112. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202:135-143.
113. Aeberli D., Seitz M., Jüni P., Villiger P.M. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford) 2005, 44:172-175.
114. Gifre L., Ruiz-Esquide V., Xaubet A., Gomez-Puerta J.A., Hernandez M.V., Sanmarti R. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol 2011, 47:208-212.
115. Skoie I.M., Wildhagen K., Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int 2010.
116. Kanellopoulou T., Filiotou A., Kranidioti H., Dourakis S.P. Sarcoid-like granulomatosis in patients treated with anti-TNFalpha factors. A case report and review of the literature. Clin Rheumatol 2011, 30:581-583.
117. Daïen C.I., Monnier A., Claudepierre P., Constantin A., Eschard J.P., Houvenagel E., et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009, 48:883-886.
118. Pietinalho A., Hiraga Y., Hosoda Y., Lofroos A.B., Yamaguchi M., Selroos O. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995, 12:61-67.
119. Takahashi H., Kaneta K., Honma M., Ishida-Yamamoto A., Ashida T., Kohgo Y., et al. Sarcoidosis during infliximab therapy for Crohn's disease. J Dermatol 2010, 37:471-474.
120. Korsten P., Sweiss N.J., Nagorsnik U., Niewold T.B., Grone H.J., Gross O., et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 2010, 56:e17-21.
121. Olivier A., Gilson B., Lafontaine S., Pautot J.X., Bindi P. Sarcoïdose pneumo-rénale apparue sous anti-TNFα. Rev Med Interne 2011, Epub ahead of print, [accessed 5.30.11].
122. Takatori S., Kamata Y., Murosaki T., Iwamoto M., Minota S. Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept. J Rheumatol 2010, 37:210-211.
123. van der Stoep D., Braunstahl G.J., van Zeben J., Wouters J. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. J Rheumatol 2009, 36:2847-2848.
124. Dhaille F., Viseux V., Caudron A., Dadban A., Tribout C., Boumier P., et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010, 220:234-237.
125. Rossman M.D., Newman L.S., Baughman R.P., Teirstein A., Weinberger S.E., Miller W., et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:201-208.
126. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177-185.
127. Goldberg H.J., Fiedler D., Webb A., Jagirdar J., Hoyumpa A.M., Peters J. Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir Med 2006, 100:2063-2068.
128. Heinzerling L.M., Anliker M.D., Muller J., Schlaeppi M., von Moos R. Sarcoidosis induced by interferon-alpha in melanoma patients: incidence, clinical manifestations, and management strategies. J Immunother 2010, 33:834-839.
129. Akahoshi M., Ishihara M., Remus N., Uno K., Miyake K., Hirota T., et al. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet 2004, 114:503-509.
130. Borchers A.T., So C., Naguwa S.M., Keen C.L., Gershwin M.E. Clinical and immunologic components of sarcoidosis. Clin Rev Allergy Immunol 2003, 25:289-304.
131. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
132. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:889-894.
133. Fernández-Espartero M.C., Pérez-Zafrilla B., Naranjo A., Esteban C., Ortiz A.M., Gómez-Reino J.J., et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011, 40:330-337.
134. Bernatsky S., Renoux C., Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010, 69:1691-1693.
135. Simsek I., Erdem H., Pay S., Sobaci G., Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007, 66:1255-1258.
136. Davis S.A., Johnson R.R., Pendleton J.W. Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies. J Rheumatol 2008, 35:1469-1470.
137. Lozeron P., Denier C., Lacroix C., Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009, 66:490-497.
138. Magnano M.D., Robinson W.H., Genovese M.C. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004, 22:S134-S140.
139. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
140. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009, 60:3761-3765.
141. Kumar D., Bouldin T.W., Berger R.G. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010, 62:3191-3195.
142. Kothary N., Diak I.L., Brinker A., Bezabeh S., Avigan M., Pan G.D. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011.
143. Mohan N., Edwards E.T., Cupps T.R., Slifman N., Lee J.H., Siegel J.N., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004, 31:1955-1958.
144. Saint Marcoux B., De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006, 73:710-713.
145. Guignard S., Gossec L., Bandinelli F., Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol 2008, 26:S23-S29.
146. Jarrett S.J., Cunnane G., Conaghan P.G., Bingham S.J., Buch M.H., Quinn M.A., et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003, 30:2287-2291.
147. Hirohama D., Hoshino J., Hasegawa E., Yamanouchi M., Hayami N., Suwabe T., et al. Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-alpha. Mod Rheumatol 2010, 20:602-605.
148. Fujikawa K., Kawakami A., Hayashi T., Iwamoto N., Kawashiri S.Y., Aramaki T., et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol 2010, 20:86-89.
149. Guillevin L., Mouthon L. Tumor necrosis factor-alpha blockade and the risk of vasculitis. J Rheumatol 2004, 31:1885-1887.
150. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., Pego-Reigosa J.M., Retamozo S., Bove A., et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011.
151. Panopoulos S.T., Sfikakis P.P. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011.
152. Komiya K., Ishii H., Fujita N., Oka H., Iwata A., Sonoda H., et al. Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Med 2011, 50:749-751.
153. Kawashiri S.Y., Kawakami A., Sakamoto N., Ishimatsu Y., Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2010.
154. Lioté H., Lioté F., Séroussi B., Mayaud C., Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010, 35:681-687.
155. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Symmons D.P. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69:1086-1091.
156. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
157. Berkun Y., Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9:A319-A324.
158. Bhat A., Naguwa S., Cheema G., Gershwin M.E. The epidemiology of transverse myelitis. Autoimmun Rev 2010, 9:A395-A399.
159. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:A299-A304.
160. Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum 2007, 56:1736-1744.
161. Borchers A.T., Naguwa S.M., Keen C.L., Gershwin M.E. The implications of autoimmunity and pregnancy. J Autoimmun 2010, 34:J287-J299.
162. Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9:A277-A287.
163. Borchers A.T., Uibo R., Gershwin M.E. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010, 9:A355-A365.
164. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
165. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
166. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010, 34:J234-J246.
167. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
168. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J Autoimmun 2010, 34:J276-J286.
169. Chen M., Kallenberg C.G. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010, 9:A293-A298.
170. Deane S., Teuber S.S., Gershwin M.E. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010, 9:A342-A349.
171. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010, 9:A325-A329.
172. Gershwin M.E., Goetzl E.J., Steinberg A.D. Cyclophosphamide: use in practice. Ann Intern Med 1974, 80:531-540.
173. Hemminki K., Li X., Sundquist J., Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010, 34:J307-J313.
174. Hershko A.Y., Naparstek Y. Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 2006, 5:230-233.
175. Hoffmann M.H., Trembleau S., Muller S., Steiner G. Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010, 34:J178-J206.
176. Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun 2010, 34:J300-J306.
177. Lambert J.F., Nydegger U.E. Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 2010, 9:A350-A354.
178. Leung P.S., Shu S.A., Kenny T.P., Wu P.Y., Tao M.H. Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 2010, 9:A400-A405.
179. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
180. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
181. Mackay I.R. The etiopathogenesis of autoimmunity. Semin Liver Dis 2005, 25:239-250.
182. Mackay I.R. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 2010, 9:A251-A258.
183. Martin P.I., Malizia A.I., Rewald E. A propos time and autoimmunity. Clin Rev Allergy Immunol 2008, 34:380-384.
184. Maverakis E., Miyamura Y., Bowen M.P., Correa G., Ono Y., Goodarzi H. Light, including ultraviolet. J Autoimmun 2010, 34:J247-J257.
185. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010, 9:A305-A310.
186. Meyer A., Levy Y. Chapter 33: geoepidemiology of myasthenia gravis. Autoimmun Rev 2010, 9:A383-A386.
187. Meyer N., Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010, 9:A379-A382.
188. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9:A387-A394.
189. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34:J226-J233.
190. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:A330-A334.
191. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
192. Round J.L., O'Connell R.M., Mazmanian S.K. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010, 34:J220-J225.
193. Sands J., Tuscano J.M. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 2010, 9:A335-A341.
194. Segelmark M., Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010, 9:A366-A371.
195. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun Rev 2010, 9:A247-A250.
196. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 9:A267-A270.
197. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
198. Shoenfeld Y., Selmi C., Zimlichman E., Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008, 31:325-330.
199. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010, 9:A271-A276.
200. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 2010, 9:A288-A292.
201. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010, 34:J322-J326.
202. Tonutti E., Visentini D., Bizzaro N. Interpretative comments on autoantibody tests. Autoimmun Rev 2007, 6:341-346.
203. Youinou P., Pers J.O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010, 34:J163-J167.
204. Zeki A.A., Schivo M., Chan A.L., Hardin K.A., Kenyon N.J., Albertson T.E., et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 2010, 34:J327-J338.
205. Ramiro S., Machado P., Singh J.A., Landewe R.B., da Silva J.A. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther 2010, 12:220.
206. McInnes I.B., O'Dell J.R. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010, 69:1898-1906.
207. Koncz T., Pentek M., Brodszky V., Ersek K., Orlewska E., Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010, 10:1367-1378.
208. Tobon G.J., Saraux A., Pers J.O., Youinou P. Emerging biotherapies for Sjogren's syndrome. Expert Opin Emerg Drugs 2010, 15:269-282.
209. Kahn P. Juvenile idiopathic arthritis-current and future therapies. Bull NYU Hosp Jt Dis 2009, 67:291-302.
210. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009, 82:25-32.
211. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
212. Cuchacovich R., Hagan J., Khan T., Richert A., Espinoza L.R. Tumor necrosis factor-alpha (TNF-alpha)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol 2011, 30:133-137.
213. Farah M., Al Rashidi A., Owen D.A., Yoshida E.M., Reid G.D. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 2008, 35:349-351.
214. Izzi S., Francesconi F., Visca P., Altieri A., De Mutiis C., Trevisan G., et al. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. Dermatol Online J 2010, 16:16.
215. Kerjouan M., Jouneau S., Lena H., Luraine R., Desrues B., Delaval P. Sarcoïdose pulmonaire apparue sous étanercept [Pulmonary sarcoidosis developing during treatment with etanercept, Article in French with English abstract]. Rev Mal Respir 2011, 28:360-364.
216. Metyas S.K., Tadros R.M., Arkfeld D.G. Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 2009, 29:437-439.
217. Massara A., Cavazzini L., La Corte R., Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2010, 39:313-319.
218. Pink A.E., Fonia A., Smith C.H., Barker J.N. The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. Br J Dermatol 2010, 163:648-649.
219. Bensouda-Grimaldi L., Mulleman D., Valat J.P., Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol 2007, 34:239-240. discussion 40.
220. Gomez-Gallego M., Meca-Lallana J., Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008, 59:91-93.
221. Tanno M., Nakamura I., Kobayashi S., Kurihara K., Ito K. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 2006, 25:929-933.
222. Ibrahim W.H., Hammoudah M., Akhtar N., Al-Hail H., Deleu D. Central nervous system demyelination associated with etanercept in a 51 years old woman. Libyan J Med 2007, 2:99-102.
223. Cay H.F., Gungor H.A., Sezer I., Kacar C., Balci N. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 2006, 31:645-648.
224. Martínez-Taboada V.M., Val-Bernal J.F., Pesquera L.C., Fernández-Llanio N.E., Esteban J.M., Blanco R., et al. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 2006, 35:322-323.
225. Al Saieg N., Luzar M.J. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol 2006, 33:1202-1204.
226. Bellesi M., Logullo F., Di Bella P., Provinciali L. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol 2006, 253:668-669.
227. Kameda T., Dobashi H., Kittaka K., Susaki K., Hosomi N., Deguchi K., et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol 2008, 18:399-402.
228. Kur-Zalewska J., Swarowska-Knap J., Tlustochowicz W. Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. Pol Arch Med Wewn 2008, 118:234-237.